CAR-T cell therapies have been a game-changer for cancer treatment. However, there is room for improvement as heterogeneous antigen expression leads to tumor relapse. Additionally, CAR-T cell therapies have underperformed in solid tumors due to immunosuppressive microenvironments. In this webinar brought to you by IsoPlexis, Jessica Morris from Baylor College of Medicine will discuss two strategies for improving the efficacy of CAR-T cell therapies in leukemia and solid tumors.
Topics to be covered
Increasing the targeting capabilities of CAR-T cells to multiple tumor-associated antigens
Mechanisms of T cell activation and deactivation
Thursday, July 15, 2021
3:00 - 4:00 PM Eastern Time
Meet the speaker
Jessica Morris PhD Candidate Center for Cell and Gene Therapy Baylor College of Medicine Texas Children's Hospital
Register Now
TS_WEBINAR_LabTools_IsoPlexis_Enhancing the Efficacy of CAR T-Cell Therapies July 15, 2021_IO#402360
You must have Javascript and Cookies enabled to access this webcast.
Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
